Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children
Abstract Introduction Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in patients down to ag...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Adis, Springer Healthcare
2025-01-01
|
| Serier: | Dermatology and Therapy |
| Fag: | |
| Online adgang: | https://doi.org/10.1007/s13555-024-01318-6 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
